STOCK TITAN

Vaccinex, Inc. - VCNX STOCK NEWS

Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.

Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.

The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.

Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.

Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.

Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.

Rhea-AI Summary
Vaccinex reports positive findings for its lead product, pepinemab, in treating brain inflammation. The drug significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, indicating its potential to reverse harmful astrocyte activation. A randomized, placebo-controlled trial is currently underway to test the drug's effectiveness in Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
-
Rhea-AI Summary
Vaccinex, Inc. announces securities purchase agreements for the sale of 9.6M shares of common stock and warrants, expected to raise $9.6M in gross proceeds. The funds will be used for the development of its lead drug candidate and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.17%
Tags
-
Rhea-AI Summary
Vaccinex announces a new publication in the journal mAbs describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery. The application was successfully used with OmniAb's platform to select antibodies against challenging multipass membrane targets. This new application is a powerful complement to Vaccinex's ActivMAb platform and can accelerate the development of novel therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.82%
Tags
none
Rhea-AI Summary
Vaccinex to present update on Phase 1b/2 pepinemab/PDAC study and new ActivMAb® application
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
conferences
-
Rhea-AI Summary
Vaccinex, Inc. will report on novel findings for its lead product, pepinemab, at upcoming medical conferences. Results from the phase 2 SIGNAL trial suggest pepinemab has the potential to prevent decline in brain metabolic activity and slow cognitive decline in Huntington's disease. In combination with a checkpoint inhibitor, pepinemab has shown the potential to induce formation of lymphoid structures in tumors, leading to improved outcomes in head and neck cancer. The company believes pepinemab may be an attractive alternative or combination therapy for Alzheimer's disease. The Phase 2 KEYNOTE-B84 study demonstrated improved objective response rates and progression-free survival in head and neck squamous cell carcinoma patients treated with pepinemab and KEYTRUDA. Treatment with pepinemab in combination with KEYTRUDA also appeared to induce formation of highly organized lymphoid structures in tumors, which correlated with disease control and progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.64%
Tags
none
-
Rhea-AI Summary
Vaccinex, Inc. announces a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.67%
Tags
none
Rhea-AI Summary
Vaccinex, Inc. announced financial results for Q2 2023 and provided updates on clinical milestones. The Phase 1b/2 SIGNAL-AD trial of pepinemab in Alzheimer's disease achieved full accrual and is expected to complete 12-months treatment in June 2024. Interim results from the Phase 2 KEYNOTE-B84 trial in head and neck cancer showed promising outcomes. Vaccinex is also initiating clinical studies in metastatic pancreatic cancer and breast cancer. The company's cash and cash equivalents were $1.9 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
Rhea-AI Summary

Vaccinex, a biotechnology company focusing on neurodegenerative diseases, has successfully completed enrollment for its SIGNAL-AD clinical trial, aimed at evaluating pepinemab in patients with mild Alzheimer's Disease. The trial, which included 40 patients, is designed to assess safety and cognitive effects over a 52-week period. Results are expected in mid-2024. The company builds on previous positive data from its Huntington’s Disease study, reinforcing the potential of pepinemab to address neuroinflammation. Moreover, FDA feedback on a planned Phase 3 study for Huntington’s Disease is anticipated by May 16, 2023. The ongoing SIGNAL-AD trial has been supported financially by key organizations in Alzheimer’s research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags

FAQ

What is the current stock price of Vaccinex (VCNX)?

The current stock price of Vaccinex (VCNX) is $1.12 as of December 24, 2024.

What is the market cap of Vaccinex (VCNX)?

The market cap of Vaccinex (VCNX) is approximately 3.0M.

What is Vaccinex, Inc.?

Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies, vaccines, and biologic products to treat serious diseases, including cancer and autoimmune diseases.

Where is Vaccinex, Inc. located?

Vaccinex, Inc. is based in Rochester, NY.

What is Vaccinex's lead drug candidate?

Vaccinex's lead drug candidate is pepinemab, which targets semaphorin 4D (SEMA4D) and is being studied for its potential to treat cancer and neurodegenerative diseases.

What is the focus of Vaccinex's research?

Vaccinex focuses on treating serious diseases with unmet medical needs, such as cancer, multiple sclerosis, and other autoimmune diseases.

What clinical studies is pepinemab involved in?

Pepinemab is currently being evaluated in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease.

What is the ActivMAb platform?

ActivMAb is Vaccinex's proprietary drug discovery platform that aids in the development of its innovative therapeutic products.

Who are Vaccinex's research partners?

Vaccinex collaborates with world-class academic institutions and biotechnology companies for its discovery research.

What recent milestone has Vaccinex achieved?

Vaccinex recently completed a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards.

How is Vaccinex funded?

Vaccinex has received significant investments and grants, including funding from the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association.

Who leads the development team at Vaccinex?

Vaccinex's development team is led by experienced industry veterans with expertise in various fields such as therapeutic biologics research, manufacturing, and regulatory affairs.

Vaccinex, Inc.

Nasdaq:VCNX

VCNX Rankings

VCNX Stock Data

3.00M
2.37M
9.37%
49.12%
4.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ROCHESTER